Not currently recruiting at UCSF
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
- ID
- NCT03518086
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1281 people participating
- Last Updated